Systemic sclerosis at the cellular level: molecular pathways of pathogenesis and its implication on future drug design.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current Medicinal Chemistry

• Publication date

  2009-09-30

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/092986709789352259PMID 19747128
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The pathology of scleroderma vascular disease.

  2008cited by this paper
• EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells

  2008cited by this paper
• Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?

  2008cited by this paper
• Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease

  2008cited by this paper
• Autologous stem cell transplantation improves microcirculation in systemic sclerosis

  2008cited by this paper
• Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity

  2008cited by this paper
• Vascular disease in scleroderma: mechanisms of vascular injury.

  2008cited by this paper
• Maximum blood flow and microvascular regulatory responses in systemic sclerosis.

  2007cited by this paper
• Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis.

  2007cited by this paper
• Bone marrow endothelial progenitors are defective in systemic sclerosis.

  2006cited by this paper
• Variations of neuronal nitric oxide synthase in systemic sclerosis skin.

  2006cited by this paper
• Endothelial Apoptosis and Chronic Transplant Vasculopathy: Recent Results, Novel Mechanisms

  2006cited by this paper
• Novel Fibrogenic Pathways Are Activated in Response to Endothelial Apoptosis: Implications in the Pathophysiology of Systemic Sclerosis1

  2005cited by this paper
• Damage of cutaneous peripheral nervous system evolves differently according to the disease phase and subset of systemic sclerosis.

  2005cited by this paper
• Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon.

  2005cited by this paper
• Mechanisms of Raynaud’s disease

  2005cited by this paper
• Pathogenesis of Raynaud's phenomenon.

  2005cited by this paper
• Induction of endothelial cell damage by hCMV molecular mimicry.

  2005cited by this paper
• Calcitonin gene-related peptide-like immunoreactivity in nerve fibers in the human skin

  2004cited by this paper
• Endothelial Progenitor Cells: Characterization and Role in Vascular Biology

  2004cited by this paper
• Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

  2004cited by this paper
• Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis

  2004cited by this paper
• Endothelial dysfunction and reactive oxygen species production in ischemia/reperfusion and nitrate tolerance.

  2004cited by this paper
• Defective vasculogenesis in systemic sclerosis.

  2004cited by this paper
• Rho Kinase Mediates Cold-Induced Constriction of Cutaneous Arteries: Role of &agr;2C-Adrenoceptor Translocation

  2004cited by this paper
• Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study.

  2004cited by this paper
• Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease.

  2004cited by this paper
• The vasculopathy of Raynaud's phenomenon and scleroderma.

  2003cited by this paper
• Vascular damage and lack of angiogenesis in systemic sclerosis skin

  2003cited by this paper
• Myofibroblasts and mechano-regulation of connective tissue remodelling

  2002cited by this paper
• Complement activation by apoptotic endothelial cells following hypoxia/reoxygenation

  2001cited by this paper
• Vascular adrenoceptors: an update.

  2001cited by this paper
• Effect of temperature and modulators of protein tyrosine kinase activity on the reactivity of isolated venules in secondary Raynaud's phenomenon.

  2001cited by this paper
• Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma.

  2001cited by this paper
• The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis.

  2001cited by this paper
• Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95.

  2000cited by this paper
• Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries.

  2000cited by this paper
• Nitric Oxide Down-regulates MKP-3 mRNA Levels

  2000cited by this paper
• Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension

  2000cited by this paper
• Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma.

  2000cited by this paper
• Differential expression of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma

  2000cited by this paper
• Vascular function in systemic sclerosis

  2000cited by this paper
• Oxygen-derived free radical-induced vasoconstriction by thromboxane A2 in aorta of the spontaneously hypertensive rat.

  1999cited by this paper
• Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon: effects of oral L-arginine supplementation.

  1999cited by this paper
• Autoimmunity and vascular involvement in systemic sclerosis (SSc).

  1999cited by this paper
• Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma.

  1999cited by this paper
• Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension.

  1998cited by this paper
• Apoptosis of endothelial cells is associated with paracrine induction of adhesion molecules: evidence for an interleukin-1beta-dependent paracrine loop.

  1998cited by this paper
• The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis.

  1998cited by this paper
• Microvascular involvement in systemic sclerosis: laser Doppler evaluation of reactivity to acetylcholine and sodium nitroprusside by iontophoresis

  1998cited by this paper
• Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera.

  1997cited by this paper
• Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension.

  1997cited by this paper
• Nitric oxide synthase: role in the genesis of vascular disease.

  1997cited by this paper
• Raynaud's phenomenon.

  1996cited by this paper
• IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines.

  1996cited by this paper
• Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.

  1996cited by this paper
• Response of digital arteries to endothelium dependent and independent vasodilators in patients with Raynaud's phenomenon

  1995cited by this paper
• The evolution of Raynaud's phenomenon: a longterm prospective study.

  1995cited by this paper
• Localization of endothelin-1 and its binding sites in scleroderma skin.

  1994cited by this paper
• Activation of the alternative pathway of human complement by apoptotic human umbilical vein endothelial cells.

  1994cited by this paper
• Venodilation in Raynaud's disease.

  1993cited by this paper
• Molecular mechanisms of nitric oxide regulation. Potential relevance to cardiovascular disease.

  1993cited by this paper
• Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon.

  1993cited by this paper
• Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy

  1992cited by this paper
• Significance of plasma endothelin-1 levels in patients with systemic sclerosis.

  1992cited by this paper
• Image analysis quantification of peptide‐immunoreactive nerves in the skin of patients with Raynaud's phenomenon and systemic sclerosis

  1991cited by this paper
• Nitric oxide: physiology, pathophysiology, and pharmacology.

  1991cited by this paper
• Biosynthesis and metabolism of endothelium-derived nitric oxide.

  1990cited by this paper
• Endothelium‐derived relaxing and contracting factors

  1989cited by this paper
• Elevated von Willebrand factor antigen in systemic sclerosis: relationship to visceral disease.

  1988cited by this paper
• Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma.

  1982cited by this paper
• Skin capillary changes in early systemic scleroderma. Electron microscopy and "in vitro" autoradiography with tritiated thymidine.

  1976cited by this paper
• Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls.

  1969cited by this paper

• RNA Interference against Platelet-Derived Growth Factor Receptor α mRNA Inhibits Fibroblast Transdifferentiation in Skin Lesions of Patients with Systemic Sclerosis

  2013influential citation
• Prevalence and clinical importance of gastroesophageal reflux in Chinese patients with systemic sclerosis.

  2012cites this paper
• Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis.

  2010cites this paper